COVID-19：卫材开始“ Eritlan”的临床试验：严重脓毒症/候选药物
卫材
该公司宣布将开始针对新的冠状病毒感染性疾病“ Eritlan”的临床试验（临床试验），Eritlan是严重脓毒症的候选药物。
新的电晕感染有望具有“阻止导致严重呼吸系统疾病的免疫功能失控的作用”。
我们将在全球范围内进行400人的临床试验，并计划于6月开始临床试验。
据说最早将在一年内获得结果。
“ REMAP-CAP-COVID”：参与
卫材将参加“ REMAP-CAP-COVID”以开发用于新电晕感染的治疗剂。
卫材将利用这一框架提供作为潜在治疗剂的eritoran和先进的临床试验。
厄立特里亚：
卫材正在开发的一种可用于治疗严重脓毒症的药物。
由于它抑制了细胞因子产生的最上游过程，因此有望从根本上阻止免疫失控。
日本经济新闻
https://r.nikkei.com/article/DGXMZO59056060T10C20A5XB0000?s=0
Our Response to the Novel Coronavirus Infection
May 15th, 2020
Eisai is conducting activities in response to the novel coronavirus infection such as support of the development of novel coronavirus remedies, the ensuring of stable supply of medicines, and the support of aid efforts being conducted in various different countries.
Contribution to Development of Remedies
Regarding the TLR4 (Toll-Like Receptor 4) inhibitor eritoran (E5564), created and developed internally as a sepsis treatment,
Eisai is participating in the international network REMAP-CAP-COVID (Randomized, Embedded, Multi-factorial, Adaptive Platform-Community Acquired Pneumonia COVID)
which aims for novel coronavirus medicine development through drug repurposing, and is to begin an international collaborative clinical trial in June 2020 which is designated for confirmed novel coronavirus patients who are hospitalized and are in a progressing disease state.
Regarding cytokine production, which is the cause of the cytokine storm that is strongly indicated as participating in the worsening of pneumonia and other symptoms of the novel coronavirus,
it is hoped that through suppressing the most upstream TLR4 activity, the production of multiple cytokine types will be suppressed and pneumonia and other symptoms can thus be prevented from becoming severe.
Eisai Co., Ltd.